AstraZeneca: Saxa-dapa might be approved this weekBUY, Fair Value 5400p (+30%)
Saxa-dapa is a key asset for AZN’s diabetes franchise which could be approved in the US as early as this week. In April 2014, AZN said it could be a USD3bn opportunity. We are not yet at this level but an approval would be a clear incentive for AZN to support its diabetes franchise further.
For more information, please contact firstname.lastname@example.org